StockData
Sana Biotechnology, Inc. logo

Sana Biotechnology, Inc. (SANA) stock

SANANasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 5/30
$1.85−0.03 (-1.60%)

Close on Nov 18, 2026Market cap $553.82MP/E –Yield –

Sana Biotechnology r&d expenses

Research and development expenses are spending on new products and technology.

Sana Biotechnology's R&D Expenses for the twelve months ending Jun 30, 2026 was $124.48M, down 24.7% year over year. For fiscal 2025 it was $131.98M, down 38.8% from the year before. The highest annual figure on record is $285.89M in fiscal 2022.

Annual r&d expenses

PeriodPeriod endValueChange
FY2025Dec 31, 2025$131.98M-38.8%
FY2024Dec 31, 2024$215.67M-17.6%
FY2023Dec 31, 2023$261.81M-8.4%
FY2022Dec 31, 2022$285.89M+15.0%
FY2021Dec 31, 2021$248.63M+87.0%
FY2020Dec 31, 2020$132.94M+33.5%
FY2019Dec 31, 2019$99.59M–

Quarterly r&d expenses

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$30.73M+3.3%
Q1 FY2026Mar 31, 2026$28.72M-22.8%
Q4 FY2025Dec 31, 2025$34.92M-22.6%
Q3 FY2025Sep 30, 2025$30.11M-43.4%
Q2 FY2025Jun 30, 2025$29.76M-51.1%
Q1 FY2025Mar 31, 2025$37.19M-34.1%
Q4 FY2024Dec 31, 2024$45.15M-19.4%
Q3 FY2024Sep 30, 2024$53.21M-18.9%
Q2 FY2024Jun 30, 2024$60.87M-16.7%
Q1 FY2024Mar 31, 2024$56.45M-16.0%
Q4 FY2023Dec 31, 2023$55.99M-12.4%
Q3 FY2023Sep 30, 2023$65.61M-14.5%
Q2 FY2023Jun 30, 2023$73.04M+0.7%
Q1 FY2023Mar 31, 2023$67.17M-7.6%
Q4 FY2022Dec 31, 2022$63.92M-41.1%
Q3 FY2022Sep 30, 2022$76.74M+44.1%
Q2 FY2022Jun 30, 2022$72.54M+61.2%
Q1 FY2022Mar 31, 2022$72.69M+73.6%
Q4 FY2021Dec 31, 2021$108.51M+197.3%
Q3 FY2021Sep 30, 2021$53.25M+32.9%
Q2 FY2021Jun 30, 2021$45.00M+50.0%
Q1 FY2021Mar 31, 2021$41.88M+53.3%
Q4 FY2020Dec 31, 2020$36.49M–
Q3 FY2020Sep 30, 2020$40.06M–
Q2 FY2020Jun 30, 2020$29.99M–
Q1 FY2020Mar 31, 2020$27.32M–

More Sana Biotechnology figures

See a number that looks wrong?